Nadia Dandachi

Graz, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Common analysis pitfalls in longitudinal ctDNA studies: lead time, sensitivity and immortal time bias.

Common analysis pitfalls in longitudinal ctDNA studies: lead time, sensitivity and immortal time bias.

Journal: EBioMedicine

Published: March 04, 2026

Aberrant methylation limits antitumoral inflammation in lung adenocarcinoma by restricting RIPK3 expression.

Aberrant methylation limits antitumoral inflammation in lung adenocarcinoma by restricting RIPK3 expression.

Journal: Science advances

Published: January 21, 2026

Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria.

Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria.

Journal: ESMO open

Published: November 21, 2025

Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial.

Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial.

Journal: NPJ breast cancer

Published: July 28, 2025

Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications.

Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications.

Journal: NPJ breast cancer

Published: March 22, 2025

Evaluation of urinary cfDNA workflows for the molecular profiling of malignant disease.

Evaluation of urinary cfDNA workflows for the molecular profiling of malignant disease.

Journal: iScience

Published: January 10, 2025

Circulating tumor DNA (ctDNA) trajectories predict survival in trifluridine/tipiracil-treated metastatic colorectal cancer patients.

Circulating tumor DNA (ctDNA) trajectories predict survival in trifluridine/tipiracil-treated metastatic colorectal cancer patients.

Journal: Molecular oncology

Published: December 15, 2023

Deciphering the molecular landscape of metastatic lobular breast cancer.

Deciphering the molecular landscape of metastatic lobular breast cancer.

Journal: EBioMedicine

Published: November 14, 2022

Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression.

Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression.

Journal: International journal of molecular sciences

Published: October 25, 2022

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 07, 2021

Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing-A Prospective Feasibility Study.

Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing-A Prospective Feasibility Study.

Journal: Cancers

Published: May 02, 2021

Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity.

Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity.

Journal: Cancers

Published: March 12, 2021

Showing 1-12 of 36

Last Updated: 09/26/2026